Amazon's New AI Tool Turns Years of Drug Research Into Weeks

Amazon Web Services has launched Amazon Bio Discovery, an AI-powered platform that compresses early-stage drug discovery timelines from 18 months into just weeks, enabling rapid molecule design, antibody generation, and lab-in-the-loop testing.

Key Highlights

• Launch Date: April 2026
• Purpose: Accelerate early-stage drug discovery using AI-driven workflows
• Compression of Timelines: From 12–18 months to weeks
• No Coding Required: Scientists can run workflows without programming
• AI Foundation Models: Specialized biological models generate and evaluate molecules
• Lab-in-the-Loop: Candidates synthesized and tested with results fed back

Achievements & Adoption

Feature	Details
Antibody Generation	300,000 novel antibodies generated; 100,000 tested
Industry Adoption	Used by Bayer, Broad Institute, and 19 of top 20 pharma companies
Research Partners	Memorial Sloan Kettering reported sub-nanomolar affinity antibodies
Free Trial	AWS offers trial access for researchers

How It Works

AI agent helps scientists set up and run AI-powered drug discovery workflows.

• Model Selection: AI agents guide researchers
• Candidate Screening: Millions narrowed to 100–1,000 top candidates
• Optimization: AI refines therapeutic properties
• Integration: Results loop back into system knowledge

Risks & Considerations

• Validation Needed: Wet-lab testing required
• Regulatory Oversight: Compressed timelines challenge frameworks
• Data Dependence: Accuracy depends on training datasets
• Not a Replacement: Supports researchers, not replaces them

Impact for India & Global Pharma

With India’s growing biotech and pharma sector, platforms like Amazon Bio Discovery could accelerate vaccine and therapeutic development, especially in oncology, infectious diseases, and rare disorders.

Globally, this represents a paradigm shift in R&D efficiency, reducing costs and speeding access to life-saving drugs.

Emergence of AI based Drug Discovery

More than 200 AI-designed drugs are now in clinical development, with Phase I success rates of 80–90%, nearly double traditional averages. Big Pharma Adoption: In early 2026, Eli Lilly, GSK, and Pfizer signed major deals with AI drug discovery platforms, signaling mainstream adoption.

Several AI-driven platforms besides Amazon Bio Discovery are reshaping drug discovery in 2026, including Insilico Medicine, Recursion Pharmaceuticals, and Exscientia, all of which are delivering clinical candidates and accelerating pharma R&D.

Rubicon Expands India Presence with Arinna Acquisition, Eyes Deep CNS Market

Rubicon Research Limited (“Rubicon” or the “Company”) today announced the acquisition of an 85% equity ownership in Arinna Lifesciences Limited (“Arinna”) from its current shareholders.

Mr. Parag Sancheti, Chief Executive Officer, Rubicon Research Limited

With a portfolio of over 60 brands in chronic therapies, Arinna is one of the few domestic formulations companies principally focused on drugs treating conditions of the central nervous system (“CNS”) with more than 4,000 prescribers backed by an established distribution network of distributors, stockists and retail pharmacies in India.

This acquisition furthers Rubicon’s strategy of leveraging its IP and chronic products portfolio to unlock growth in key markets, particularly in the CNS therapeutic category which has always been a core focus area for Rubicon. Arinna’s sales and distribution network provides Rubicon access to patients and prescribers in India for its differentiated offerings, including a strong pipeline of specialty products and drug-device combinations.

Commenting on the acquisition, Parag Sancheti, Rubicon’s Chief Executive Officer said “The past decade has demonstrated the effectiveness of Rubicon’s playbook of R&D innovation, execution rigor and impeccable compliance standards which enabled us to scale our US revenues by over 32 x from FY15 to FY25 while delivering best-in-class return ratios. Arinna now provides us a launchpad for deploying this playbook in the Indian domestic formulations market. Strategic M&A has always been integral to Rubicon’s strategy and our confidence stems from having successfully integrated and scaled acquisitions to foray into new segments such as US branded specialty in 2024 and nasal products development in 2020. I am pleased to welcome Vivek and the Arinna team to the Rubicon family.”

The transaction values Arinna at an enterprise value of INR 200 Crores on a cash and debt free basis. After accounting for net cash and other necessary adjustments to the enterprise value of Arinna, the purchase consideration has been determined to be approximately INR 175.92 Crores for secondary acquisition of 85% equity shareholding at a price of INR 158.53 per share. The final consideration remains subject to adjustments on the closing date, if any. For the 9 months ended 31 December 2025, Arinna’s provisional revenue and EBITDA were INR 56.7 Crores and 9.5 Crores respectively.

The transaction is expected to close within 30 days upon satisfaction of agreed conditions precedent. Arinna’s founder Vivek Seth will retain a 15% ownership interest and continue as Arinna’s Managing Director.

About Rubicon Research Limited

Rubicon Research Limited is an integrated pharmaceutical company focused on the development, manufacturing, and commercialization of differentiated pharmaceutical products. Established in 1999, Rubicon has evolved from a contract development services organization into a vertically integrated pharmaceutical platform encompassing research and development, CDMO capabilities, and branded and generic product commercialization.

Rubicon currently has a portfolio of 80+ pharmaceutical products across multiple therapeutic areas, including a meaningful portfolio of CNS products. The company operates globally inspected manufacturing facilities in India regulated by authorities including the U.S. Food and Drug Administration, UK MHRA, and Australian TGA. Rubicon also maintains a strong R&D organization of over 200 scientists across development centres in Mumbai and Toronto, reflecting deep formulation expertise and a strong focus on differentiated drug delivery technologies.

Rubicon is a public company, listed on the National Stock Exchange of India and BSE Limited.

NIPER Mohali Partners Novartis to Boost Pharma Research with Prestigious Grant

National Institute of Pharmaceutical Education and Research (NIPER), Mohali, has signed a landmark agreement with Novartis Healthcare Private Limited (NHPL) to strengthen academia‑industry collaboration in pharmaceutical research. The partnership includes the prestigious Development Pioneer Grant, awarded to a NIPER Mohali faculty member, positioning India’s pharma education ecosystem closer to global innovation standards.

The signing ceremony, held in New Delhi, was witnessed by Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, along with senior officials and representatives from Novartis.

The Development Pioneer Grant

• Agreement signed between NIPER Mohali and Novartis Healthcare Private Limited (NHPL) in New Delhi.
• Witnessed by Shri Manoj Joshi, Secretary, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
• One faculty member from NIPER Mohali awarded the Development Pioneer Grant for NIPERs, supported by Novartis.
• Out of 42 proposals submitted across seven NIPERs, one was chosen after rigorous evaluation by an independent jury.
• Grant aims to promote cutting‑edge research, encourage innovation‑driven partnerships, and align academic work with industry requirements.

Government’s Vision

The Department of Pharmaceuticals has consistently highlighted the need for stronger industry‑academia linkages. Senior officials including Shri Awadhesh Kumar Choudhary, Dr. Kinny Singh, Prof. Dulal Panda, Prof. Joydev Kumar Laha, Mr. Amitabh Dube, and Ms. Sadhna Joglekar were present during the ceremony, underscoring the government’s commitment to nurturing innovation in India’s pharmaceutical sector.

• Shri Manoj Joshi emphasized the importance of moving beyond pilot projects to ensure research is effectively integrated with industry needs.
• The Department of Pharmaceuticals envisions stronger industry‑academia linkages to enhance India’s role in global healthcare innovation.
• Senior officials including Shri Awadhesh Kumar Choudhary, Dr. Kinny Singh, Prof. Dulal Panda, Prof. Joydev Kumar Laha, Mr. Amitabh Dube, and Ms. Sadhna Joglekar attended the ceremony.

About Novartis

Novartis, headquartered in Basel, Switzerland, is one of the world’s leading pharmaceutical companies, consistently ranked among the top five globally by revenue. The company has undergone a strategic transformation into a pure‑play medicines firm, focusing exclusively on innovative therapies while divesting non‑core businesses such as generics and vaccines.

In recent years, Novartis has reported strong growth driven by breakthroughs in oncology, immunology, cardio‑renal‑metabolic disorders, and neurology. It has also invested heavily in advanced platforms including radioligand therapy, gene and cell therapy, and xRNA technologies. Beyond commercial success, Novartis maintains a strong commitment to global health challenges, working on treatments for malaria, sickle cell disease, Chagas disease, and leprosy. This global positioning makes Novartis a powerful partner for Indian institutions like NIPER, enabling knowledge transfer, research collaboration, and integration into international innovation networks.

Significance for India

• Strengthens NIPER Mohali’s role in India’s pharmaceutical innovation ecosystem.
• Provides faculty with global exposure and competitive platforms to advance research.
• Drives pioneering healthcare advancements that benefit both academia and industry.
• Reinforces India’s ambition to become a global hub for pharmaceutical innovation.

The partnership between NIPER Mohali and Novartis marks a milestone in India’s pharma education and research landscape. By combining academic expertise with industry resources, the initiative is set to accelerate innovation, nurture talent, and reinforce India’s position in global pharmaceutical research.

India’s Pharma & MedTech Ecosystem Strengthened Through Infrastructure, Innovation, and Access Schemes

India’s pharmaceutical and medical technology sectors are undergoing a transformative phase, driven by a series of government-backed schemes that combine infrastructure development, innovation support, affordability initiatives, and regulatory strengthening. Together, these measures are positioning India as a global hub for pharmaceuticals, medical devices, and biopharmaceuticals.

Bulk Drug and Medical Device Parks

The Scheme for Promotion of Bulk Drug Parks is enabling the creation of common infrastructure for bulk drug manufacturing. Three parks have been approved in Andhra Pradesh, Gujarat, and Himachal Pradesh, with a combined project cost exceeding ₹6,306 crore. Each park is receiving ₹1,000 crore in central assistance.

The Scheme for Promotion of Medical Devices Parks supports advanced testing and laboratory facilities. Parks in Greater Noida (Uttar Pradesh), Ujjain (Madhya Pradesh), and Kanchipuram (Tamil Nadu) are at advanced stages of development, with a total project cost of ₹871 crore.

• 199 medical device manufacturers allotted land
• 306.64 acres distributed across three parks
• 34 units have commenced construction

Research, Innovation, and Affordable Access

The Promotion of Research and Innovation in Pharma MedTech (PRIP) scheme is fostering innovation-driven growth.

• 7 Centres of Excellence established at NIPERs
• 111 research projects approved
• 46 papers published
• 6 patents filed

The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has expanded access to low-cost medicines.

• 18,646 Jan Aushadhi Kendras operational
• 2,110 medicines and 315 medical devices available
• Over 100 crore sanitary pads sold at ₹1 each
• ₹8,000 crore savings for citizens in FY 2024-25
• ₹5,637 crore savings up to November 2025

Biopharma SHAKTI Initiative

Announced in the Union Budget 2026-27, Biopharma SHAKTI will invest ₹10,000 crore over five years to establish India as a global biopharmaceutical hub.

• Creation of biopharma-focused institutional network
• 3 new and 7 upgraded NIPERs
• 1,000 accredited clinical trial sites planned

Regulatory and Pricing Framework

India’s pharmaceutical governance is anchored by a strong regulatory ecosystem:

• CDSCO oversees drug approvals, clinical trials, and pharmacovigilance
• NPPA regulates drug prices under DPCO 2013
• IPC publishes the Indian Pharmacopoeia, recognized in 19 countries

Conclusion

India’s pharmaceutical ecosystem is evolving into a globally integrated, policy-supported system that balances scale, affordability, and regulatory credibility. Upcoming trade agreements with the European Union, United Kingdom, and New Zealand are expected to further enhance India’s pharmaceutical and medical devices sector.

Ramky Infra to Build India’s Largest Integrated Life Sciences City at Dighi Port

Ramky Infrastructure Limited (RIL) today announced the execution of a Concession Agreement between the Maharashtra Industrial Development Corporation (MIDC) and Maha Integrated Life Sciences City Limited (MILeS City), a wholly owned subsidiary of Ramky Infrastructure Limited, for the development of a High-Tech Pharmaceutical Park at the Dighi Port Industrial Area in Raigad district, Maharashtra.

The project will be implemented on a Public-Private Partnership (PPP) basis under the Design, Build, Finance, Operate and Transfer (DBFOT) model, with an estimated project cost of INR 3,000 crore excluding the operating income to be generated during the 90 years operation period. The concession period will span 95 years, including a construction period of five years which RIL expects to execute in coming 5 years would form part of the Order Book of RIL aggregating it to INR 13,500 Crores.

The proposed High-Tech Pharmaceutical Park will be developed across approximately 1,000 hectares within the Dighi Port Industrial Area, covering parts of Mangaon and Roha talukas in Raigad district. The project will establish a large-scale integrated development comprising industrial zones, commercial areas, common infrastructure, utilities, internal road networks and designated open spaces.

An Integrated Life Sciences Manufacturing Ecosystem

The project is designed to establish a world-class integrated life sciences manufacturing ecosystem that will provide end-to-end infrastructure and shared facilities for pharmaceutical, biotechnology, and life sciences companies.

Key elements of the proposed development include:

– Integrated infrastructure and advanced utilities, enabling industries to optimise capital investment and improve operational efficiency.

- Innovation-led research and development centres, incubation hubs, and technology transfer platforms to encourage collaboration, capability building, and sectoral innovation.

- Environmentally responsible infrastructure that supports high standards of environmental safety, regulatory compliance, and sustainable industrial operations.

Under the terms of the concession agreement, MILeS City will be responsible for the development, operation, maintenance and management of the project for the entire concession period.

The revenue model for the project will include:

• Land lease premium and lease rental
• Development charges
• Maintenance charges for common infrastructure and services
• Operational charges for utilities and shared facilities

The project is expected to strengthen industrial infrastructure in the region, attract investments into the pharmaceutical and life sciences sectors, and generate significant direct and indirect employment opportunities. It is also anticipated to stimulate growth in ancillary industries and local businesses across the surrounding areas.

Following the execution of this concession agreement, the order book position of Ramky Infrastructure Limited stands at approximately INR 13,500 crore, reflecting the company’s continued momentum in large-scale infrastructure and industrial development projects.

Commenting on the development, Mr. Sunil S Nair, CEO, Ramky Infrastructure Limited said, “This agreement marks a significant milestone not only for industrial development, but for the wider communities and businesses that stand to benefit from it. By creating a large-scale integrated life sciences ecosystem at Dighi Port Industrial Area, we see an opportunity to support employment generation, strengthen regional infrastructure, encourage innovation, and attract long-term investment into Maharashtra. The project is designed to enable pharmaceutical and biotechnology companies to grow within a well-supported and globally competitive manufacturing environment."

About Ramky Infrastructure Limited

Ramky Infrastructure Limited is the flagship infrastructure development company of the Ramky Group and has been a prominent player in the infrastructure sector since its establishment in 1994. The company has successfully delivered a wide range of projects spanning industrial infrastructure, water and wastewater treatment, roads, bridges, and urban infrastructure development.

Headquartered in Hyderabad, the company operates across India and international markets with a team of more than 2,000 professionals.

Ramky Infrastructure Limited is certified under ISO 9001:2015 (Quality Management Systems), ISO 14001:2015 (Environmental Management Systems), and ISO 45001:2018 (Occupational Health and Safety Management Systems), which guide the company’s practices in design, engineering, procurement, and construction of infrastructure projects.

Granules India Expands R&D Footprint with Two CoEs at IIT Hyderabad for Peptides and Particle Engineering

Granules India Limited today inaugurated two advanced Centres of Excellence at the Technology Research Park of IIT Hyderabad: the Ascelis Center of Excellence for Peptide Development and Characterization and the Granules Center of Excellence for Particle Engineering.

The inauguration was led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India, Mrs. Uma Chigurupati, Executive Director, Granules India Limited & Prof. B S Murty, Director, IITH

Ascelis Center of Excellence for Peptide Development and Characterization, established under Ascelis Peptides, the CDMO arm of Granules, this Centre will drive the development of cosmetic, therapeutic, and pharmaceutical peptides. It is Ascelis’ first development and characterization facility in India and is equipped for primary, secondary, and tertiary structure characterization. The Center brings advanced analytical and process development capabilities in-house and will work in collaboration with our Swiss-based R&D facility Senn Chemicals, strengthening the group’s integrated global peptide offering and reducing reliance on external partners.

Granules Center of Excellence for Particle Engineering, This Centre will advance polymorph research, material science, and novel drug delivery systems, including amorphous solid dispersions. It replaces earlier external and ad-hoc development with a dedicated research platform that enables first-to-file opportunities, enhances formulation performance, and supports the creation of proprietary technologies for regulated markets.

Speaking at the inauguration, Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India, said: “Scientific excellence and rigorous research have always shaped our long-term strategy at Granules. The launch of these Centres of Excellence significantly strengthens our capabilities in peptides and advanced material sciences, areas that will define the next wave of pharmaceutical innovation. With specialised infrastructure and deep scientific expertise, we are enhancing our CDMO ambitions, accelerating breakthrough development, and building differentiated technologies that elevate our global competitiveness and deliver meaningful value to our partners and patients worldwide.”

About Granules India Ltd. (BSE: 532482, NSE: GRANULES)

Granules India Limited, incorporated in 1991 is a vertically integrated fast growing Indian pharmaceutical company headquartered at Hyderabad with best-in-class facilities and commitment to operational excellence, quality, and customer service. We are among the few pharmaceutical companies in the world to be present in the manufacturing of entire value chain – from Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs) and Peptides CDMO. Our products are being distributed to over 300+ customers in regulated and semi-regulated markets with a global presence extending to over 80+ countries with offices across India, US and Switzerland. The Company has 11 manufacturing facilities out of which 8 are in India, 2 in the USA and 1 in Switzerland and has regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, K FDA, DEA, MCC, and HALAL. For more information about Granules India Ltd and its initiatives, please visit www.granulesindia.com

Cough Syrup Horror: Banned Chemical Used, Pharma Firm Under Probe

The Special Investigation Team (SIT) probing the Coldrif cough syrup tragedy in Madhya Pradesh has confirmed that industrial-grade diethylene glycol—a toxic chemical used in brake fluids and antifreeze—was present in the syrup that led to the deaths of 23 children, including 20 in Chhindwara district.

Key Findings from the SIT Investigation:

• Source of Contamination: The chemical was traced to Sresan Pharmaceuticals, owned by Ranganathan Govindan in Tamil Nadu. He allegedly procured banned industrial-grade diethylene glycol for production.
• Supply Chain Mapping: Investigators are now examining the entire supply chain—from raw material sourcing to distribution—to determine how long the chemical had been used and who else may be complicit.
• Accountability Focus: Authorities aim to fix responsibility at every stage, including suppliers, intermediaries, and production oversight. Govindan initially claimed ignorance, saying production was delegated.

Source: Times of India | The Indian Express [October 11, 2025] 

The Coldrif cough syrup tragedy was first reported by several national and regional outlets, but among the earliest and most locally grounded coverage came from India Today, on October 7, by reporter Ravish Pal Singh, based in Bhopal. The report highlighted the rising death toll in Chhindwara and Betul districts, naming victims and linking the deaths to Coldrif syrup containing toxic substances.

Regulatory Implications

This case has reignited calls for tighter pharmaceutical oversight and raw material traceability. It echoes past tragedies involving toxic syrups and highlights the urgent need for reform in drug manufacturing protocols.

Eli Lilly to Invest Over $1 Billion in India to Expand Global Drug Manufacturing

Eli Lilly and Company today announced plans to invest more than $1 Billion over the next several years into new contract manufacturing in India, expanding patients’ access to innovative medicines around the world. This strategic investment will further strengthen the manufacturing and supply capabilities to support our evolving portfolio.

In addition, Lilly will establish a new Manufacturing & Quality presence in Hyderabad. This new hub will offer advanced technical capabilities and oversight for Lilly’s contract manufacturing network across India. Recruitment will begin immediately, with openings across roles such as engineers, chemists, analytical scientists, quality control and assurance professionals, and management positions. This initiative reflects Lilly’s intent to leverage India’s highly skilled talent pool to support its global manufacturing growth and deliver medicines to patients worldwide. Since 2020, Lilly has committed more than $55 billion to build, expand, and acquire facilities in the U.S. and around the world. These facilities and investments address growth from potential new medicines to treat diabetes and obesity, Alzheimer’s disease, cancer and autoimmune conditions and prepare for medicines of the future.

Shri A. Revanth Reddy, Hon’ble Chief Minister of Telangana, said, “Lilly’s continued expansion in Hyderabad highlights the city’s emergence as a powerhouse in global healthcare innovation. From the recent opening of its Innovation and Technology site to a new manufacturing collaboration and the establishment of a Manufacturing & Quality hub, Lilly is moving swiftly to expand its presence in Telangana — reinforcing the state’s position as a preferred destination for cutting-edge healthcare investments.”

Shri Sridhar Babu, Hon’ble Minister for Information Technology, Electronics & Communications, Industries & Commerce and Legislative Affairs, Telangana, added, “Lilly’s expansion in Hyderabad is a testament to Telangana’s dynamic industrial landscape and its growing influence in advanced healthcare manufacturing. The state’s focus on technology-driven infrastructure and ease of doing business continues to attract global leaders across sectors and lifesciences sector in particular has been on accelerated growth.”

Nivruti Rai, Managing Director & CEO, Invest India, Ministry of Commerce & Industry, Govt. of India, said, "Lilly’s investment in India reflects not only the country’s rise as a competitive global manufacturing and innovation hub, but also Lilly’s own commitment to growth, innovation, and advancing healthcare worldwide. This partnership reflects confidence in India’s skilled talent, robust infrastructure, and business-friendly policies, while supporting Lilly’s journey as a global leader in life sciences. Together, we are shaping a stronger future for healthcare and manufacturing. We are proud to support Lilly’s growth journey in India and wish them continued success in the years ahead."

“We are making significant investments to increase manufacturing and medicine supply capacity around the world to help ensure patients have access to the medicines they need,” said, Patrik Jonsson, Executive Vice President and President Lilly International, Eli Lilly and Company. “Working with trusted contract manufacturers expands our capabilities to deliver life-changing medicines at greater scale — with quality always at the core. This investment reaffirms our confidence in India as a hub for capability building within our global network.”

With a longstanding presence in India, including a commercial site in Gurugram and specialized sites in Bengaluru and Hyderabad that serve as important hubs supporting global innovation, Lilly is reinforcing its commitment to the country through strategic investments in local talent and technical capabilities.

About Lilly

Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.

Laborate's Aqualab’s Direct-to-Retail Model Scales Fast: ₹100 Cr Achieved, ₹250 Cr in Sight

Aqualab, the Direct-to-Retail division of Laborate Pharmaceuticals India Ltd, has crossed the ₹100 crore revenue mark within three years of launch and now expects to touch ₹250 crore by FY 25–26. The growth has been driven by an expanding portfolio of over 800 SKUs and a network of 500+ retail stockists, with Tier-II and Tier-III markets contributing a rising share of sales.

Since its inception in 2022, the division has reported consistent year-on-year growth, moving from ₹76 crore in FY 2022–23 to ₹108 crore in FY 2023–24, Aqualab has focused on ensuring affordability and last-mile access, enabling its medicines to reach smaller towns alongside metropolitan centres.

“Crossing ₹100 crore in three years demonstrates how quickly the Direct-to-Retail model is scaling in India. We are now targeting ₹250 crore by FY 25–26, with non-metro markets expected to contribute 42% of incremental growth. Expanding therapeutic categories and strengthening last-mile delivery will remain our key focus areas,” said Arpit Bhatia, Managing Director, Laborate Pharmaceuticals.

Aqualab’s rise is in step with national priorities such as Make in India and the government’s PLI push to boost domestic pharma manufacturing. The retail pharmacy market, pegged at ₹18,700 crore in FY24, is projected to touch ₹31,200 crore by FY32, growing at a CAGR of 6.6% on the back of stronger generic penetration, greater health awareness, and organised distribution. Leveraging this momentum, Aqualab is preparing to expand into new categories, add facilities, adopt digital channels, and explore exports, consolidating its position in India’s retail pharma landscape.

Laborate’s WHO, GMP, and EU GMP-certified facilities have provided Aqualab with the infrastructure to scale rapidly while maintaining international quality standards. The company operates modern plants with advanced manufacturing and quality control systems, enabling compliance with stringent benchmarks. This foundation has not only supported Aqualab’s domestic expansion but also positions the division for potential export opportunities in the future.

About Laborate Pharmaceuticals

Founded in 1985, Laborate 1 is one of the leading pharmaceutical companies in India, with capabilities in manufacturing, R&D, and global distribution. The company provides pharmaceutical products in therapeutic categories that include CVS, Diabetics, Pain Management, CNS, and other general categories, and has presence in 55 countries worldwide.

Laborate’s facilities are cGMP compliant with several regulatory agencies including WHO-GMP, and now EU-GMP compliance. With innovation, quality, and affordability as the cornerstones of its strategy, Laborate is able to provide drugs in both branded and contract manufacturing capacities, to its clients

Anthem Biosciences Wins Big with Oversubscribed IPO

Anthem Biosciences is making waves with its ₹3,395 crore IPO, which has been fully subscribed on Day 2 of bidding, reflecting strong investor confidence amid a global pharma pivot from China to India.

Company Snapshot

Founded in 2006, Anthem is a Contract Research, Development, and Manufacturing Organization (CRDMO).

• Offers end-to-end drug discovery, development, and manufacturing services.
• Specializes in fermentation-based APIs like probiotics, enzymes, peptides, and biosimilars.
• Facilities are cGMP-compliant, approved by USFDA, ANVISA, TGA, and PMDA.

IPO Highlights

• Price Band: ₹540–₹570 per share.
• Grey Market Premium (GMP): ₹116–₹121, suggesting a ~20% listing gain.
• Subscription Status (Day 2):
• Overall: 2.08x subscribed
• Non-Institutional Investors (NIIs): 5.75x
• Retail: 1.78x
• Qualified Institutional Buyers (QIBs): 44%
• Anchor Investors: Raised ₹1,016 crore from names like Abu Dhabi Investment Authority, Norges Bank, and Societe Generale.
• Listing Date: Tentatively July 21, 2025, on BSE and NSE.

📈 Analyst Sentiment

Brokerages are bullish:

• Motilal Oswal: “Well positioned to capitalize on market opportunities.”
• Anand Rathi: “Profitable track record, strong growth potential.”
• SBI Securities: “Fairly priced with superior margins and returns”.

With big pharma diversifying away from China, Anthem is well-positioned to capture outsourced CRDMO demand, especially in biologics and specialty APIs.

Hillchol®: Bharat Biotech’s Oral Cholera Vaccine Demonstrates Success in Phase III Clinical Studies

Bharat Biotech’s Oral Cholera Vaccine Hillchol® has demonstrated against both Ogawa and Inaba serotypes, proving non-inferior in healthy Indian adults and children, supporting its potential as an effective OCV.

The above study findings have been published in the ScienceDirect, Vaccine journal 126998 to assess a double-blind, randomized phase III clinical trial to evaluate safety, immunogenicity, non-inferiority & lot-to-lot consistency of single component oral cholera vaccine Hillchol® in comparison to a comparator vaccine in a diverse participant group of 1,800 individuals, from infants to adults, across 10 clinical sites in India. In this study, participants were divided into three age groups: adults over 18 years, children aged 5 to under 18 years, and infants aged 1 to under 5 years. They were randomized in a 3:1 ratio to receive either Hillchol® or a comparator vaccine.

The primary endpoint focused on the proportion of participants achieving >4-fold increase in vibriocidal antibody titres against Ogawa and Inaba serotypes 14 days after two doses. While secondary endpoints included Geometric Mean Titre (GMT) measurements and safety.

Key highlights from the findings:

• Robust Immunogenicity: Hillchol® demonstrated a greater than 4-fold rise in vibriocidal antibodies against both Ogawa (68.3%) and Inaba (69.5%) serotypes, proving non-inferiority to licensed vaccines.
• Strong Safety Profile: Adverse events were mild and comparable between the two vaccines. Broad Age Coverage: The vaccine was well-tolerated and immunogenic across all age groups—including infants (≥1 year), children, and adults.

"This publication reaffirms our commitment to advancing vaccines built on rigorous research, thorough clinical trials, and reliable clinical data. It highlights our continued commitment to providing affordable, effective, and accessible vaccines for the populations who need them the most,” said Dr. Krishna Ella, Executive Chairman of Bharat Biotech.

Dr. Ella added, “Cholera is a vaccine-preventable disease that has faced a surge in outbreaks along with a huge shortage of vaccines. The new generation Oral Cholera Vaccine Hillchol®, featuring a simplified single stable O1 Hikojima strain, inducing robust antibodies against both Ogawa and Inaba serotypes, aims to enhance production efficiency and affordability, particularly in lower- and middle-income countries where waterborne diseases continue to pose serious health threats.”

Cholera is an acute diarrhoeal infection caused by ingesting food or water contaminated with Vibrio cholerae bacteria. Studies have estimated that 2.86 million cases and 95,000 deaths occur annually.

HillChol® Pack

With Hillchol®, Bharat Biotech strengthens its commitment to combating global infectious diseases through innovation and clinical excellence. As cholera continues to threaten communities lacking clean water and sanitation, Hillchol® provides a streamlined, scalable solution designed to support global health programs and ensure equitable access to life-saving vaccines.

Global demand for OCVs is close to 100 million doses a year, and given that only one manufacturer supplies them, there is a global shortage. Bharat Biotech's facilities in Hyderabad and Bhubaneswar have a capacity to produce up to 200 million doses of Hillchol®.

Published in the ScienceDirect, Vaccine journal: https://www.sciencedirect.com/science/article/pii/S0264410X25002956?via%3Dihub

About Bharat Biotech:

Bharat Biotech has established an excellent track record of innovation with more than 145 global patents, a wide product portfolio of more than 19 vaccines, 4 biotherapeutics, registrations in more than 125 countries, and the World Health Organization (WHO) Pre-qualifications. Located in Genome Valley in Hyderabad, India, a hub for the global biotech industry, Bharat Biotech has built a world-class vaccine & bio-therapeutics, research & product development, Bio-Safety Level 3 manufacturing, and vaccine supply and distribution. Having delivered more than 9 billion doses of vaccines worldwide, Bharat Biotech continues to lead innovation and has developed vaccines for influenza H1N1, Rotavirus, Japanese Encephalitis (JENVAC®), Rabies, Chikungunya, Zika, Cholera, and the world’s first tetanus-toxoid conjugated vaccine for Typhoid.

Bharat’s commitment to global social innovation programs and public-private partnerships resulted in introducing path-breaking WHO pre-qualified vaccines BIOPOLIO®, ROTAVAC®, ROTAVAC 5D®, and Typbar TCV® combatting polio, rotavirus, typhoid infections, respectively. HILLCHOL®, an oral vaccine against cholera, was launched in 2024. The acquisition of Chiron Behring Vaccines has positioned Bharat Biotech as the world's largest rabies vaccine manufacturer with Chirorab® and Indirab®. To learn more about Bharat Biotech, visit www.bharatbiotech.com.

Pharma Companies Mallinckrodt, Endo in Talks to Merge

Pharmaceuticals companies Mallinckrodt Pharmaceuticals and Endo International are reportedly in discussions about a potential merger. The deal, which could be valued at around $7 billion, would result in each company owning roughly 50% of the combined entity. The merged company is expected to be listed on the New York Stock Exchange.

Both companies have faced significant legal challenges in recent years due to their involvement in the U.S. opioid epidemic. Mallinckrodt emerged from its second bankruptcy in November 2023, while Endo returned from bankruptcy last year.

The merger could potentially help them navigate these challenges more effectively.

Notably, both Mallinckrodt and Endo have faced significant legal challenges, primarily related to their involvement in the U.S. opioid epidemic.

Mallinckrodt has been involved in extensive litigation related to opioid sales and pricing practices. The company filed for Chapter 11 bankruptcy in 2023 to address its long-term debt and opioid obligations. As part of its financial restructuring plan, Mallinckrodt agreed to a $1.6 billion settlement to address claims related to the opioid crisis. The company also initiated examinership proceedings in Ireland to implement certain aspects of its financial restructuring.

Endo International has also faced significant legal challenges due to its involvement in the opioid crisis. The company filed for Chapter 11 bankruptcy in 2022 after agreeing to a $6 billion settlement with creditors to address outstanding lawsuits related to its marketing and promotion of opioid products.

Endo has also been involved in litigation with the FDA and bulk compounders over the production of vasopressin, a drug used to treat low blood pressure.

Both companies have taken steps to restructure their finances and address their legal obligations, but they continue to face challenges related to their past actions in the opioid crisis.

Impact of Merger in India Operations 

In India, Mallinckrodt Pharmaceuticals operates through its subsidiary, Mallinckrodt Pharmaceuticals India Private Limited. The company was incorporated on November 27, 2012, and is classified as a subsidiary of a foreign company. It is involved in the manufacture of basic Chemicals.

However, it appears that the company's operations in India are currently inactive, as its status is listed as "Strike Off".

Endo International has a more active presence in India. The company operates several manufacturing facilities in the country, including locations in Indore, Chennai, Mumbai, and Dhar.

Notably, Endo received U.S. FDA approval for its manufacturing facility in Indore, which is designed for the aseptic manufacturing of sterile injectable products. This facility is expected to significantly increase Endo's sterile injectable production capacity and expand its future growth potential.

The merger could lead to increased investment in these India facilities, enhancing production capabilities and expanding the range of products manufactured in India. Additionally, the merger could result in the consolidation of resources, leading to improved efficiency and cost saving.

The combined entity could leverage its expanded product portfolio to capture a larger share of the Indian pharmaceutical market.

India Develops Indigenous Technology to Produce Paracetamol Domestically and Reduce Import

The Council of Scientific and Industrial Research (CSIR) has developed indigenous technology to produce paracetamol, a widely used pain reliever and fever reducer. This innovation aims to reduce India's dependence on imported raw materials for paracetamol production, aligning with Prime Minister Narendra Modi's vision of Atmanirbhar Bharat (self-reliant India).

Karnataka-based Satya Deeptha Pharmaceuticals Ltd will utilize this breakthrough to produce affordable paracetamol domestically. This move is expected to make India self-reliant in paracetamol manufacturing and contribute to the country's pharmaceutical self-sufficiency.

Notably, India imports the key raw materials for paracetamol production from several countries. The primary sources include China, Germany, and France. This reliance on imports has been a significant factor in the development of indigenous technology by CSIR to produce paracetamol domestically.

India has made significant strides in developing indigenous drugs namely India’s 1st Indigenously developed Antibiotic- Nafithromycin to treat both atypical and typical drug-resistant bacteria.

Earlier, India has also conducted first successful trial of gene therapy for treating haemophilia, a blood disorder. The Modi government in India also led successful cultivation of lavender and other aromatic plants under the Aroma Mission initiative.

These advancements highlight India's growing capabilities in pharmaceuticals and other sectors. It's an exciting time for innovation in the country.

Eli Lilly Set to Become World's First $1 Trillion Drugmaker by Market Value

Eli Lilly is on the verge of becoming the world's first pharmaceutical company to reach a market value of $1 trillion. This milestone is driven by the soaring demand for its treatments for diabetes and obesity, such as Zepbound and Mounjaro.

According to Financial Times, "Wall Street's insatiable appetite for weight-loss drug stocks looks set to turn the company into the world's first $1tn drugmaker by market value. But investors wonder if Eli Lilly has reached 'peak enthusiasm'?"

The company's market capitalization has surged significantly, reaching around $898 billion as of July 2024.

Eli Lilly’s stock has surged about 58% in 2024, driven by the success of its weight-loss drugs and strong earnings.

This achievement would place Eli Lilly among an exclusive group of companies, mostly dominated by tech giants like Apple, Amazon, and Microsoft. It's a remarkable testament to the company's growth and the increasing investor confidence in its innovative treatments.

Eli Lilly is making significant strides in the weight loss drug market with its two blockbuster drugs, Mounjaro and Zepbound. These drugs have become highly popular due to their claims of being effective in treating obesity and type 2 diabetes.

Very recently, Eli Lilly announced a $4.5 billion investment to build the Lilly Medicine Foundry in Lebanon, Indiana. This state-of-the-art facility will focus on advanced drug manufacturing and development, combining research and production in one location. It’s expected to open in late 2027 and will support the company’s growing pipeline.

The new facility will help increase the production of popular drugs like Mounjaro and Zepbound, which are in high demand for treating diabetes and obesity. This expansion aims to address current supply shortages and meet future demand.

The drugmaker has invested $20 billion in manufacturing facilities over the past four years.

The Lilly Medicine Foundry will enable the development of new production methods and technologies, which will be transferred to other manufacturing sites for full-scale production. This initiative is part of Lilly’s broader strategy to innovate and optimize its manufacturing processes.

Lilly is also expanding its manufacturing capabilities in Limerick, Ireland, with a $1 billion investment. This expansion aims to increase the production of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro.

The company has 11 obesity drugs in its pipeline and is working on developing more treatments for Alzheimer’s disease, ALS, and other brain diseases. This reflects Eli Lilly’s commitment to addressing a wide range of health challenges.

Besides this, Eli Lilly is planning to expand its research center in India. This move aims to leverage India’s growing capabilities in pharmaceutical research and development.

In October 2021, Eli Lilly has entered into a strategic partnership with Cipla to enhance access to its key diabetes products, such as Humalog and Trulicity. This partnership allows Cipla to sell, promote, and distribute these products in India, leveraging Cipla’s robust distribution network.

These initiatives highlight Eli Lilly’s ongoing efforts to innovate and expand its capabilities in drug manufacturing and development.

Eli Lilly’s stock has been buoyed by the high demand for its diabetes and obesity treatments, particularly Mounjaro and Zepbound, as well as its strategic investments in new manufacturing facilities.

Eli Lilly’s stock is performing strongly with Current Price of $891.07 USD. The stock has traded between $516.57 and $972.53 over the past year. The drugmaker's total revenue stood at $11.3 billion, a 36% increase from the previous year.

Eli Lilly’s revenue growth rate of 36% year-over-year is notably higher than the industry average, showcasing strong demand for its products. Notably Eli Lilly’s revenue is primarily driven by its successful diabetes and obesity treatments, such as Mounjaro and Zepbound.

While companies like Johnson & Johnson and Pfizer have higher overall revenues due to their diversified portfolios, Eli Lilly’s focused approach on high-demand treatments has led to impressive growth.

Hyderabad Distt Has the Largest Number of USFDA-approved Manufacturing Pharmaceutical Units in the World, Followed by New Jersey : Dr E. Vishnu Vardhan Reddy

Dr E Vishnu Vardhan Reddy IFS, Special Secretary, Investment Promotion and  NRI Affairs, Joint MD, TSTPC speaking at the session

Business Session on CEPA and Related Business Opportunities held

It seems CEPA is more tailor-made to Telangana because the state has several sectors which have greater export potential: Dr E. Vishnu Vardhan Reddy, IFS, Special Secretary, Investment Promotion & NRI Affairs, Joint Managing Director (TSTPC) 

The Federation of Telangana Chambers of Commerce and Industry (FTCCI) in association with UAE-India Business Council (UIBC), New Delhi organised a Business Session on Comprehensive Economic Agreement (CEPA) and Related Business Opportunities in the city at Hotel Park, Rajbhavan Road on Thursday night.

FTCCI is the most vibrant regional chamber in India. UAE – India Business Council (UIBC) is the only Official Joint Business Chamber set up by both the Governments--India and the UAE for promoting economic synergy between the UAE and India.

The session aimed to highlight the Comprehensive Economic Partnership Agreement (CEPA) & Related Business Opportunities between the UAE and Telangana, India. It focused on sectors such as Plastics, Pharmaceuticals, Gems & Jewellery many others informed Mr. Mukesdh Kalra, Head--Business, Development, UIBC.

Percy Avari, Sharad AgarwalHE Aref Alnuaimi, Consul General of UAE, Dr E Vishnu Vardhan Reddy and Meela Jajadev

H. E Aaref Alnuaimi, Consul General of UAE at Hyderabad and Dr E. Vishnu Vardhan Reddy, IFS, Special Secretary, Investment Promotion & NRI Affairs, Joint Managing Director (TSTPC) were Chief Guests.

Addressing the gathering Dr Vishnu Vardhan Reddy spoke about how Telangana could best use CEPA. CEPA is a Comprehensive Economic Partnership Agreement (CEPA) that is a free trade agreement between two countries. In this case, it is between UAE and India.

CEPA is more comprehensive than Free Trade Agreements. The CEPA provides preferential market access for over 80% of products traded between India and the UAE. The CEPA covers 11 broad service sectors and more than 100 sub-sectors, such as business services, communication services, financial services, tourism, and transport services. 

The Significance of the India-UAE CEPA is it is expected to increase bilateral trade in goods to USD 100 billion within five years of the signed agreement and increase trade in services to USD 15 billion, leading to wider social and economic opportunities in both nations.

Addressing the 200-plus trade gathering in this light of background Dr Vishun Vardhan Reddy said it looks like CEPA was more tailor-made to Telangana, not because the chief negotiator of this (Mr. Srikar K. Reddy), was from Telangana, but because of our export potential and strengths of several sectors such as pharmaceuticals, engineering goods, electronics, chemicals and minerals as well as agro products.

The Telangana state stands to benefit from the agreements, Dr Vishnu Vardhan said. The state wants its exports to grow. Telangana has got huge potential. The state stands first in several areas in India. One-third of human vaccines are produced here. Accounting for 40 per cent of the total bulk drug production in India, Telangana is known as the bulk drug Capital of India. Hyderabad District has the largest number of USFDA-approved manufacturing pharmaceutical companies for a single province in the world which is 214 units. The second largest is in New Jersey with 189 units. he said.

Gems and Jewellery is another promising sector for exports, which are likely to record double-digit growth. Food Processing is another promising sector with export potential. Today we are a number of rice-producing states in India. Last year we beat Punjab in rice production. Five Colours revolutions---green, white, yellow, pink and blue to propel Telangana to the next phase of growth, he informed

Speaking further he added that soon India's largest freshwater aqua park is coming up in Telangana. India's biggest Textile Park "Kakatiya Mega Textile Park is coming up in Warangal spread over 1350 Acres. It is the largest Textile Park in India. It boasts of fibre to fashion. Chief Minister Mr K Chandra Shekhar Rao is likely to inaugurate it in September. The park is fully occupied. We have identified Furniture and Toys as a new emerging sector to focus on. A focused Toys Park, an exclusive Furniture Park, and a dedicated Gems and Jewellery Park are also coming up in the state. The state is also working on revamping its export strategies. We will have comprehensive strategies. The work is in progress and shared with the senior foreign affairs bureaucrat. UAE is a priority country for Telangana state for exports, he said.

Giving his welcome address, the newly sworn-in President of FTCCI Mr. Meela Jayadev said it is the first anniversary of India-UAE CEPA implementation. This business session is timely and topical too. CEPA is the growth engine for India-UAE bilateral trade and makes a significant impact on India's bilateral trade with the UAE especially India's exports to the UAE. India is UAE's second-largest trading partner accounting for 9% of its total foreign trade and 14% of non-oil exports. Also, the UAE is India's third biggest trade partner. FTCCI works with larger industries, MSMEs and small businesses and we have seen big potential in our exporter members from Telangana contributing significantly to our country's exports.

Mr Sharad Agarwal, CEO-India, Emirates NBD Bank and Board Member of UIBC gave opening remarks. India and UAE's long friendship was further cemented with CEPA. CEPA is a game changer. It helps in the speed of processing of trade.

A panel discussion on Business Opportunities Post India-UAE CEPA was held. It was moderated by Kunal Wadhwa, Partner PwC. Giving his opening remarks explained how CEPA is different from FTA (Free Trade Agreement)

Mr Anurag Sehgal, MD of Price Waterhouse & Co. LLP said the pandemic made every country release to the fact to have a reliable trade partner. The international trade community is looking at India as the most reliable and secure trade partner.

Unnikrishnan, Joint Director General of FIEO-The Federation of Indian Export Organisations an apex body of Indian export promotion organisations set up jointly by the Ministry of Commerce, Government of India and private trade and industry. India signed 13 FTAs (Free Trade Agreements) so far for ensuring greater market access for domestic goods and promoting exports. The booming pharma and jewellery sectors have propped up Telangana's exports.

Another panellist R Uday Bhaskar, Director General Pharmexcil observed that the pact CEPA will boost bilateral merchandise trade and it is likely to expand the presence of Made-in-India medicines in Middle Eastern countries. India’s exports to the UAE hit US$31.3 billion in FY 2022-23 due to the CEPA trade deal. Indian companies are benefitting immensely from this he said.

Mr.Vidyasagar Hariharan, Vice President, Trade Product Manager, Global Transaction Banking, Mashreq India said CEPA is much more than FTA. It is a win-win pact for both countries. It benefits MSMEs. UAE is the gateway to Africa.

Mr. Ananthanarayana S. Partner, Price Waterhouse & Co LLP asked What is the difference in CEPA compared to other free trade agreements? CEPA is more comprehensive and ambitious than an FTA because it includes services, investment, IPR, government procurement, disputes, and regulatory aspects of the trade. An FTA, in contrast, focuses only on goods. The other salient features are the safeguard mechanism of domestic trade. Whenever imports surge and cause a threat to domestic industry, it safeguards. The mechanism is inbuilt in this among others he said.

Percy Avari, Country Manager, Aramex India spoke about the synergetic role of logistics in India-UAE CEPA's Triumph.

Ms Ebtesam Alkaabi, Head of Sales, Jebel Ali Free Zone (JAFZA), Dubai making a presentation on it said that it is a community and ecosystem where industries such as logistics, e-commerce, petrochemicals and 14 other industries thrive.

Mr AVPS Chakravarthi, Chair of, the International Trade & Business Relations Committee, FTCCI said the Al Minhad area, the 84 km stretch, in the United Arab Emirates, renaming as 'Hind City' by the ruler of Dubai, Sheikh Mohammed bin Rashid Al Maktoum shows India and UAE affinity.

Mr Shubhransh Srivastav, Head of Corporate Affairs of DP World, an Emirati multinational logistics company based in Dubai, United Arab Emirates, specialising in cargo logistics, and port terminal operations, responding to Dr E. Vishnu Vardhan Reddy's appeal to look at Telangana as an investment opportunity, said that the world view of the Telangana state was that of the most enabling state. We are keenly interested in Telangana. We have already heavily invested in India. You will see me and our company more often here. We ensure seamless and painless trade, he added.

Mr Suresh Kumar Singhal, Senior Vice President and Ms Khyati Naravane, CEO of FTCCI and others graced participated in the business session.

 

LAY SCIENCES Globally Launches 'ImmunIgY', the 1st Pre-formed Oral Antibody that Neutralizes SARS-COV-2 and All Known Variants Including DELTA and OMICRON

ImmunIgY, has been developed by ReaGene Biosciences, Kyntox Bio and ProdigY, and is an antibody-containing beverage (ImmunIgY™) that can potentially prevent viral entry, regardless of vaccination or infection status

Lay Sciences, Inc. announced today that its flagship product ImmunIgY, the first-in class product that contains pre-formed (instant) antibodies that neutralize SARS-CoV-2 virus. ImmunIgY is also effective against the Delta and Omicron variants of the virus. ImmunIgY when used as an “oral rinse and swallow” product is a useful addition in preventing the onset, transmission, and progression of the disease.

ImmunIgY – The “Instant Antibodies” in ImmunIgY is based on a futuristic IgY technology and established scientific principles which allows the antibodies to attach to the virus at the point of entry into our body and neutralizes it. The antibodies in ImmunIgY are derived from hyperimmunized chicken eggs and is safe for human consumption. It specifically targets the viral protein that binds to human cell receptors to gain entry to cells of the mouth and throat-a major access point for the virus. Formulated as an orange flavoured powder, ImmunIgY easily dissolves in drinking water and is used as a beverage following oral rinsing and swishing.

Passive immunity through preformed antibodies has the potential to provide immediate protection against the SARS-CoV-2 virus variants. Preformed polyclonal antibodies in a single product that is safe, and which can broadly neutralize the binding of multiple viral variants to its human cell ACE2 receptors in oral and pharyngeal cavity may serve as a prophylactic measure to prevent onset of infection by current and future viral variants. ImmunIgY binds to SARS-CoV-2 viral variants and could offer an additional layer of protection unlike any other strategies currently employed, by neutralizing the virus in the oropharyngeal mucosa. ImmunIgY therefore, has the potential to prevent onset of infection for at least 3 hours following its use.

ImmunIgY may be used by both vaccinated and unvaccinated individuals by augmenting the virus-neutralizing responses in the mucosal compartments where the infection onsets. Additionally, ImmunIgY has the potential to reduce viral burden and thus reduce transmission in infected individuals.

Lay Sciences officially launched ImmunIgY through its worldwide distributor HealthAngels Pvt. Ltd. (UK), in Europe, Asia and Africa, and is expected to be launched in other territories worldwide over this quarter. ImmunIgY has received the European market (CE-Mark) approval by the European Union.

“ImmunIgY offers yet another line of defence against the onslaught of rapidly evolving SARS-CoV-2 viral variants. ImmunIgY is simple to use: the orange flavoured powder is readily soluble in water, and the premeasured ImmunIgY in a sachet is pasteurized and manufactured under rigorous GMP and ISO conditions and is CE marked,” said Satish Chandran, Chief Executive Officer of Lay Sciences. He further added that, “This novel solution complements existing approaches by extending protection against Delta and Omicron strains. Our innovative approach of partnership amongst the three companies; Prodigy, ReaGene and Kyntox, through their proprietary technologies and skills have enabled us to rapidly bring ImmunIgY- a first-in class product to market.”

The ImmunIgY Discovery Team led by Dr. Uday Saxena, Chief Product Ideator of ReaGene Biosciences, added, “There is a significant unmet need for new technologies designed specifically to reduce the burden of COVID-19 pandemic. The future success of COVID-19 pandemic management and improving outcomes is dependent on the development of innovative technologies as ImmunIgY. ImmunIgY’s role is a critical one, cementing the gaps and in being able to deliver neutralizing antibodies to vaccinated, infected and unvaccinated individuals, including children.”

Dr. Abhay Chopada, a renowned Consultant Surgeon at NHS UK and a Strategic Advisor to Lay Sciences said, “ImmunIgY and its underpinnings of IgY technology opens a whole new exciting weapon in the fight against current pandemic and beyond.”

Speaking at the launch of ImmunIgY, Dr. Subrahmanyam Vangala, Chief Executive Officer, ReaGene Biosciences said, “Launch of ImmunIgY marks a major milestone for management of the pandemic and the company.” Dr. Gopi Kadiyala, Chief Executive Officer of Kyntox Biotech India, and Subramanian Iyer, CSO of ProdIgY Biotech welcomed this introduction of ImmunIgY as an Over the Counter (OTC) product and described it as, “a unique proactive and safe solution in combating the pandemic.”

About Lay Sciences

Inc. Lay Sciences is a global leader in the development and commercialization of innovative, high value-added solutions to advance clinical performance, define standard of care and improve patient outcomes. Using its patented and proprietary technologies licensed from its partnering companies, ReaGene Biosciences Pvt. Ltd. in Bengaluru, India, Prodigy Biotech, Inc. in the US and Kyntox Biotech India Pvt. Ltd. in Bengaluru, India, Lay Sciences is dedicated to developing and providing innovative products focused on treating and preventing diseases of the GI tract. The company’s flagship product, ImmunIgY, is the first-in-class antibody-based oral product developed to address the pivotal step in viral entry and infection.

For more information, please visit www.myimmunigy.com or www.laysciences.com

Goel Medicos Under the Leadership of Basant Goel Organizes Blood Donation Camp Every Year

Carrying forward the novel legacy of organizing blood camp for past ten years, Goel Medicos pharmacy under the benevolent leadership of pharmacist Basant Goel, organizes blood donation camp every year in an attempt to aid those in dire need of blood.

Even during the exponential surge of coronavirus cases, Basant Goel not surrendering to the whims of the notorious virus, efficiently arranged the blood donation camps, without violating the social distancing protocol to bridge the gap in the shortage of blood that was acutely intensified by the global crisis.

 
Every year the camp arranges more than 1000 units of blood but owing to the disruption due to COVID-19, he still managed to receive 200 and 240 units in the year 2020 and 2021 respectively. As a result of this philanthropic deed, Goel Medicos has been able to save 500-1000 lives every year.

To encourage the people to come forward and donate blood, every year the campaign offers special well thought out gifts meant for the welfare of the donors. Last year helmets were gifted with the selfless motive to save the lives of people.

The blood donation camp is organized in collaboration with Guru Teg Bahadur Hospital where the people in need of blood are issued unlimited card to avail the units of blood they require.

In addition to GTB hospital, Goel Medicos also organizes blood donation camp with NGOs like Gen X and Rotary Club.

Haoma Medica Completes First-in-Human Trial for NaQuinate, a Novel Treatment in Development for Osteoporosis

LONDON , Nov. 26, 2020 /PRNewswire/ -- Haoma Medica announced today the completion of a first-in-human trial for NaQuinate, a naphthoquinone carboxylic acid, which is being developed as a novel orally administered therapeutic for osteoporosis.

The first-in-human trial initiated last year in healthy adults studied single and multiple doses of NaQuinate. The primary objective was to assess the safety, tolerability and pharmacokinetics.

''We are delighted that the first-in-human study has completed its last dosing. There were no significant safety or tolerability concerns up to the highest doses tested which underlines our expectation that NaQuinate is safe and well tolerated,'' said Dr Cenk Oguz , Haoma Medica's Chief Medical Officer.

"Our pre-clinical research has revealed an exciting feature of NaQuinate where it appears to have the capacity to work in harmony with the body's natural response to weight bearing exercise to synergistically enhance bone formation when and where required – now that would be a 'smart' drug," said Dr Steve Deacon , Haoma Medica's CEO. "Together with the safety data from this first-in-human study, this supports the potential that NaQuinate treatment could provide a safe, novel and smart therapeutic approach to bone disorders like osteoporosis and better maintain healthy skeletal aging."

About NaQuinate

Previous studies have shown NaQuinate to protect against reduction in bone quality and quantity that occurs in response to ovariectomy in rodent models.  In a mechanical mouse loading model, a surrogate for weight-bearing exercise, NaQuinate synergistically enhanced the body's normal response to loading by forming bone, targeting relevant cortical bone regions. This synergistic interaction between NaQuinate and mechanical loading suggests the functional use of bones' mechanostat, a term which describes how mechanical loading affects bone structure, in the regulation of bone mass and architecture. NaQuinate is currently being evaluated using a curative model of osteoporosis versus a bisphosphonate and a loading model versus an anabolic; results are expected early next year.

About Osteoporosis

Osteoporosis is a silent disease often not presenting with any signs or symptoms until a fracture occurs. It thus remains an underdiagnosed and undertreated disease.

Osteoporosis results in bone loss and changes in bone quality and strength that occurs through the normal aging process leading to fragile bones. Fragile bones lead to fractures, which progresses into a downward spiral of disability, loss of independence and increased mortality with considerable social and economic burden. Fragility fractures are a major obstacle to healthy aging. Worldwide there is a fragility fracture every 3 seconds.

According to the International Osteoporosis Foundation, about 200 million suffer from the disease worldwide. A combined lifetime risk of fractures is 40% and is equivalent to the risk of cardiovascular disease. In women over 45 years of age, osteoporosis results in more time in hospitals that many other diseases such as breast cancer, heart attacks, and diabetes.

About Haoma Medica

Haoma Medica is a clinical-stage biotechnology company focused on the development of therapeutics to maintain bone and vascular health.

For more information, please visit www.haomamedica.com

Investor Relations Contact:

Name: Carmen Greco

e-mail: carmen.greco@haomamedica.com

Logo - https://mma.prnewswire.com/media/1251548/Haoma_Medica_Logo.jpg

---------------------------------------------------------------------------
Visit this link to stop these emails: http://zpr.io/HSP9G

Koye Pharma raises Rs. 30 crores debt from BlackSoil Capital

Leading branded pharmaceutical company, Koye Pharma, has raised Rs. 30 crores in debt from Mumbai based NBFC - BlackSoil Capital. The company will primarily use the funds to strengthen its position in the domestic formulation market and for fueling its growth led working capital requirements.

Speaking on the debt raise, Ravindra Shenoy, Founder & Director, Koye Pharma said, “We are pleased to partner with an institution of the calibre of BlackSoil and strongly believe this association will further our long term aspirations and aid our continuous pursuit of a strong growth trajectory with enhanced focus on profitability.”  

Founded in 2013, by industry veterans Preetish Toraskar & Ravindra Shenoy with over two decades of experience each in transnational leading pharmaceutical companies like Lupin, Alkem, Novartis, Mylan, Aurobindo and Cipla.

Koye Pharma is one of the fastest growing mid-sized pharmaceutical companies offering branded pharmaceutical products across therapeutic segments including womens healthcare, respiratory care, primary care, diabetes care and consumer healthcare. The company has a pan India presence and robust distribution network covering over 1.4 lakhs retail pharmacies. It has grown at a CAGR of 42% over 4 years. The Mumbai based firm is backed by multi-stage investors Sequoia & PremjiInvest and raised significant  growth equity capital in the past 5 years. 

“Despite the changing regulation & prevailing market condition, the company has shown resilient revenue growth with work towards profitability on the back of strong network and nationwide presence, solid management team, differentiated fast growing brands and focus on niche therapeutic segments including consumer health & wellness ” said Ankur Bansal, Director, BlackSoil Capital Private Limited.

Blacksoil’s alternative credit platform has successfully concluded more than ~45 transactions to VC backed growth companies so far in the past 4 years and deployed more than 460 crores.

About Koye Pharma

Koye is a speciality pharma company which is focused on the Indian Pharmaceutical market with operations across the length and breadth of the country. It employs more than 400 qualified ambassadors who meet up more than 50000 doctors across the country every month. Koye strives to go the extra mile – to anticipate the needs of the people and provide care that exceeds expectations. Koye is set to grow widely, working towards a healthier and happier world. It is committed to heal, cure and provide general well being and happiness.

About BlackSoil

Launched in 2016 byM P Bansal and Ankur Bansal, BlackSoil is a new-age venture debt platform also focused on structured and real estate debt. Backed by family offices, Blacksoil investments have been sector agnostic as they have developed expertise in multiple domains such as Financial Services / Fintech, E-Commerce, SaaS, Logistics / Mobility, Healthcare, Consumer, travel, Industrial services, Real Estate, & many more. Some of their key investments have been in category leaders such as Oyo Rooms, EarlySalary, Chumbak, Lets Transport,Vogo, Rentomojo amongst others. BlackSoil has disbursed over INR 1600 Cr across 90+ deals in 4 years.

Atrimed Pharmaceuticals Plant Science Receives Breakthrough in Molecule Research for COVID-19 Cure by ICMR Approved Regional Centre for Biotechnology

Bangalore based Atrimed Pharmaceuticals, a pioneer in developing scientifically tested Plant based medication, announced that, three of our samples tested positive against SARS-CoV-2 in the ICMR (Indian Council for Medical Research) designated laboratory and the developed drug will be available as an Oral medicine. Company Leverages Proven Antiviral and Plant based medicinal expertise to evaluate the new approaches for treating the Novel Coronavirus Disease COVID-19. Atrimed Pharma is dedicated to develop a phytomolecule drugs for viral infections and other diseases, today takes pride that it has initiated a program to discover drug candidates for the treatment of patients infected with the novel coronavirus COVID-19, also known as SARS-CoV-2.

[caption id="attachment_151117" align="alignleft" width="257"] Dr. Hrishikesh Damle MD & CEO, Atrimed Pharmaceuticals[/caption]

Commenting on the exclusive breakthrough Dr. Hrishikesh Damle MD & CEO stated, "Based on our proven track record in virology and our capabilities in rare diseases, we believe our core competencies position us well to discover a potential treatment for COVID-19, and we are delighted to establish that three molecules out of ten submitted are passed the test and ready for Human/Clinical Trial for developing drug for the treatment of Coronavirus." He further added that these molecules were ready for scientific research in the month of March 2020 itself but took so long for clearance. "Our decision to initiate a drug discovery for COVID-19 is a natural evolution of our work and mission. Regional Centre for Biotechnology has recognised and approved 3 effective plant molecules against COVID-19 and further studies will begin shortly."

The Drug Discovery and Development Process passes through various stages which begins with Target Selection leading to discovery where in high throughput screening paves for chemical synthesis and then prepares for Vitro/Behavioural Studies and finally for Clinical/Human trial, and it is great achievement for Atrimed to take their research to their drug development to the next level.

About Atrimed Pharmaceutical Pvt Ltd.

Based in Bangalore, develops medicines from plant based molecules to develop drugs that cure diseases which have plagued humanity such as Psoriasis, Acne, Arthritis and more. It combines the traditional cures with the knowledge base created from computer aided drug design, biotechnology and Artificial Intelligence to establish a library of plant molecules, some 400,000 strong, the largest in the world. Its products cater to Skin and Hair care, Mother and Child care, and Bone related diseases, Nutrition, Metabolism and Allergies. The pharmaceutical company was sent to BIO 2019, Philadelphia, USA which is the largest Biotechnology Expo in the world by the Karnataka Government to showcase Karnataka's biotechnological ecosystem to learn more about the perspectives of high-level government officials, key thought leaders and experts from around the world on the new opportunities and challenges facing the global biotech industry.

For further information, please visit: www.atrimedbiotech.in.